Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 46.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,980 shares of the medical research company’s stock after buying an additional 1,587 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Edwards Lifesciences were worth $370,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.1 %

Shares of NYSE:EW opened at $72.89 on Thursday. The firm’s 50 day moving average price is $72.45 and its 200 day moving average price is $70.35. The stock has a market cap of $42.99 billion, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock valued at $2,799,104 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on EW. Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Citigroup increased their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.